Search by conditions:

 

Protocol Description Phase
14-035 A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation  (View details on clinicaltrial.gov) Phase I
15-105 1205-01: A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients with B-Cell Lymphomas  (View details on clinicaltrial.gov) Phase I
14-367 A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-Like Sarcomas  (View details on clinicaltrial.gov) Phase II
15-016 A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder  (View details on clinicaltrial.gov) Phase I
14-135 A Dose-Finding Phase 1 Study of TAS-120 in Patients with Advanced Solid Tumors with or without Fibroblast Growth Factor/Receptor(FGF/FGFR)- Related Abnormalities Followed by a Phase 2 Study in Patients with Advanced Solid Tumors or Multiple Myeloma FGF/FGFR-Related Abnormalities  (View details on clinicaltrial.gov) Phase II
15-271 A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study of Orally Administered PLX3397 in Patients with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath  (View details on clinicaltrial.gov) Phase III
14-537 A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, in Adult Patients With Advanced Nonhematologic Malignancies  (View details on clinicaltrial.gov) Phase I
14-389 A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)  (View details on clinicaltrial.gov) Phase I
15-259 A Multicenter Open-Label Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Lymphomas  (View details on clinicaltrial.gov) Phase II
14-031 A MULTICENTER PHASE 1 ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS  (View details on clinicaltrial.gov) Phase I
15-096 A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy  (View details on clinicaltrial.gov) Phase II
12-274 A Multicenter Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase II
14-385 A Multi-Center Phase II Trial Randomizing Novel Approaches for Graft-Versus-Host Disease Prevention Compared to Contemporary Controls  (View details on clinicaltrial.gov) Phase II
15-140 A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase I
13-412 A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Kα Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies  (View details on clinicaltrial.gov) Phase I
14-438 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-068 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase III
15-421 A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects with Relapsed or Refractory B-Cell Non-Hodgkins's Lymphoma  (View details on clinicaltrial.gov) Phase I
15-446 A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and pharmacodynamics of AMG 224 in Subjects with Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
14-118 A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-126 A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 in Combination With Radiation Plus Temozolomide or Temozolomide Alone for Subjects With Glioblastoma Multiforme  (View details on clinicaltrial.gov) Phase I
14-526 A Phase 1 Study of ABBV-221 in Subjects with Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor  (View details on clinicaltrial.gov) Phase I
14-191 A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms  (View details on clinicaltrial.gov) Phase I
13-523 A Phase 1 Study of LY3009120 in Patients with Advanced or Metastatic Cancer  (View details on clinicaltrial.gov) Phase I
14-488 A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non–Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
14-246 A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486-TsOH as a Single Agent and in Combination with Gemcitabine and nab-Paclitaxel in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-321 A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia  (View details on clinicaltrial.gov) Phase I
12-312 A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults with Ovarian Cancer and other FOLR1-Positive Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-524 A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma  (View details on clinicaltrial.gov) Phase I
15-404 A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)  (View details on clinicaltrial.gov) Phase I
14-045 A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation  (View details on clinicaltrial.gov) Phase I
13-371 A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation  (View details on clinicaltrial.gov) Phase I
11-217 A Phase 1, Open Label, Dose Escalation Study of MGA271 (Fcoptimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms Whose Vasculature Expresses B7-H3  (View details on clinicaltrial.gov) Phase I
12-461 A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas  (View details on clinicaltrial.gov) Phase I
14-543 A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-308 A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies  (View details on clinicaltrial.gov) Phase I
11-425 A Phase 1/2 Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, as Monotherapy and in Combination With Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
15-471 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer  (View details on clinicaltrial.gov) Phase I
15-242 A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia  (View details on clinicaltrial.gov) Phase II
14-195 A Phase 1/2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, A Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)  (View details on clinicaltrial.gov) Phase II
13-474 A Phase 1/2 Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase II
14-486 A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects with Advanced Solid Tumors, including Glioma, and with Angioimmunoblastic T-cell Lymphoma, that Harbor an IDH2 Mutation  (View details on clinicaltrial.gov) Phase II
14-271 A Phase 1/2a, Multicenter, Open-Label Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for TrkA, TrkB, TrkC, ROS1, or ALK Molecular Alterations  (View details on clinicaltrial.gov) Phase I
15-134 A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
14-189 A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects With Adult Solid Tumors  (View details on clinicaltrial.gov) Phase I
11-164 A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose  (View details on clinicaltrial.gov) Phase I
13-595 A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Sorafenib in Patients with Hepatocellular Cancer  (View details on clinicaltrial.gov) Phase I
14-501 A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)  (View details on clinicaltrial.gov) Phase I
14-539 A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
14-354 A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
13-562 A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib(AG-013736) In Combination with Crizotinib(PF-02341066)in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-089 A Phase 1b/2 Study of Ramucirumab in Combination with LY2875358 in Patients with Advanced Cancer  (View details on clinicaltrial.gov) Phase II
14-332 A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma  (View details on clinicaltrial.gov) Phase II
14-166 A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer  (View details on clinicaltrial.gov) Phase II
15-295 A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-566 A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
14-220 A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults with NF1-Associated Morbid Plexiform Neurofibromas  (View details on clinicaltrial.gov) Phase II
12-321 A Phase 2, Controlled Trial, of a Single ProHema-CB Unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) as Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning for Patients Age 15-55 Years with Hematologic Malignancies  (View details on clinicaltrial.gov) Phase II
13-572 A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma  (View details on clinicaltrial.gov) Phase II
13-496 A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)  (View details on clinicaltrial.gov) Phase II
15-291 A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies  (View details on clinicaltrial.gov) Phase II
14-059 A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07  (View details on clinicaltrial.gov) Phase III
15-282 A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy  (View details on clinicaltrial.gov) Phase III
14-205 A Phase 3, Multicenter, Open-Label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma  (View details on clinicaltrial.gov) Phase III
13-225 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase III
15-299 A Phase 3B, Prospective, Randomized, Open-Label, Blind Evaluator (Probe) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated with Cancer  (View details on clinicaltrial.gov) Phase III
12-487 A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors  (View details on clinicaltrial.gov) Phase I
12-283 A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
06-068 A Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066. A CMET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer  (View details on clinicaltrial.gov) Phase I
10-457 A Phase I Study of Chemoradiation with Midostaurin (PKC412) for Locally Advanced Rectal Cancer  (View details on clinicaltrial.gov) Phase I
13-581 A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Previously Treated Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
13-348 A Phase I Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins, in Patients with Progressive Lymphoma  (View details on clinicaltrial.gov) Phase I
14-580 A Phase I Study of IDH305 in Patients with Advanced Malignancies that Harbor IDH1R132 Mutations  (View details on clinicaltrial.gov) Phase I
12-202 A Phase I Study of Lenalidomide plus Chemotherapy with Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients with Acute Myelogenous Leukemia  (View details on clinicaltrial.gov) Phase I
12-491 A Phase I Study of MM-141 in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-455 A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 as a Single Agent and in Combination with Standard Chemotherapy in Patients with Advanced and/or Treatment-Refractory Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-240 A Phase I Study with a Personalized NeoAntigen Cancer Vaccine in Melanoma  (View details on clinicaltrial.gov) Phase I
15-023 A Phase I Trial Of Intensity-modulated Radiation Therapy Using A Contralateral Esophagus Sparing Technique In Locally Advanced Non-Small Cell Lung Cancer and Limited-Stage Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase I
11-209 A Phase I, Dose Escalation Study of MLN1117 in Subjects with Advanced Solid Malignancies Followed by Expansion in Subjects with Measurable Disease  (View details on clinicaltrial.gov) Phase I
13-251 A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the Fibroblast Growth Factor Receptor (FGFR) 1, 2 or 3 Genes  (View details on clinicaltrial.gov) Phase I
15-417 A Phase I, Multicenter, Open-Label, Two-Part, Dose-Escalation Study of RAD1901 in Post-Menopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer  (View details on clinicaltrial.gov) Phase I
14-562 A Phase I, multi-center, randomized open label study to assess the systemic exposure and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC)  (View details on clinicaltrial.gov) Phase I
11-314 A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously As a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-129 A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands  (View details on clinicaltrial.gov) Phase I
14-263 A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC4064A Administered Intravenously to Patients with Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer  (View details on clinicaltrial.gov) Phase I
15-074 A Phase I, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitbine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase I
12-009 A Phase I, Two-stage, Multi-center, Open Label, Dose-escalation Study of BKM120 in Combination With Adjuvant Temozolomide and With Concomitant Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov) Phase I
12-537 A Phase I/IB Study of Ipilimumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation  (View details on clinicaltrial.gov) Phase I
14-121 A Phase I/II Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC)  (View details on clinicaltrial.gov) Phase II
13-541 A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers  (View details on clinicaltrial.gov) Phase II
14-160 A Phase I/II Study of MK-3475 (SCH900475) in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma  (View details on clinicaltrial.gov) Phase II
14-355 A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination with Trametinib and Dabrafenib in Subjects with Advanced Melanoma  (View details on clinicaltrial.gov) Phase II
11-418 A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Müllerian Cancer  (View details on clinicaltrial.gov) Phase I
15-055 A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients with Advanced, ALK-Positive, Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
14-249 A Phase I/II, Multicenter, Open-Label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients with EGFRmut Solid Malignancies  (View details on clinicaltrial.gov) Phase II
14-464 A Phase I/II, Multicenter, Open-label Study of FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression  (View details on clinicaltrial.gov) Phase II
12-114 A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
13-123 A Phase Ib Open-label, Dose-escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase I
11-490 A Phase Ib Open-label, Multi-center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-218 A Phase Ib Study of CRLX101 in Combination with Weekly Paclitaxel in Patients with Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer  (View details on clinicaltrial.gov) Phase I
12-252 A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered With Bevacizumab and/or With Chemotherapy in Patients With Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-301 A Phase IB Study of the Safety and Pharmacology of MPDL3280A Administered with Cobimetinib in Patients with Locally Advanced or Metastatic Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-157 A Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase I
11-277 A Phase Ib, Open Label, Dose Escalation Study of the Safety and Pharmacology of GDC-0068 in Combination with Either Docetaxel OR Fluoropyrimidine plus Oxaliplatin in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
12-376 A Phase Ib, Open-Label Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma  (View details on clinicaltrial.gov) Phase I
15-164 A phase Ib, open-label, multicenter, dose escalation and expansion study, to evaluate the safety, pharmacokinetics and activity of INC280 in combination with cetuximab in c-MET positive CRC and HNSCC patients who have progressed after anti-EGFR monoclonal antibody therapy  (View details on clinicaltrial.gov) Phase I
13-313 A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
15-054 A Phase Ib/II Study of the ALK Inhibitor Ceritinib in Combination With the CDK4/6 Inhibitor LEE011 in Patients With ALK-positive Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
13-283 A Phase Ib/II Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive, Her2- Locally Advanced or Metastatic Breast Cancer  (View details on clinicaltrial.gov) Phase II
13-367 A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer  (View details on clinicaltrial.gov) Phase II
14-550 A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer  (View details on clinicaltrial.gov) Phase II
15-073 A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059)  (View details on clinicaltrial.gov) Phase II
14-328 A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy  (View details on clinicaltrial.gov) Phase II
15-083 A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination with Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas  (View details on clinicaltrial.gov) Phase II
15-012 A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, To Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations  (View details on clinicaltrial.gov) Phase II
14-311 A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women with ER-Positive/Her2-Negative, Early Stage Breast Cancer  (View details on clinicaltrial.gov) Phase II
15-118 A Phase II Randomized, Double-blind, Study of Ipatasertib (GDC 0068), An Inhibitor to AKT, in Combination with Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer  (View details on clinicaltrial.gov) Phase II
14-219 A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type 1 age 16 years or greater  (View details on clinicaltrial.gov) Phase II
13-163 A Phase II Study of Eribulin Mesylate in Combination with Trastuzumab and Pertuzumab in Women with Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase II
14-296 A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia  (View details on clinicaltrial.gov) Phase II
13-309 A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL  (View details on clinicaltrial.gov) Phase II
13-220 A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung  (View details on clinicaltrial.gov) Phase II
10-308 A Phase II Study Of Proton Beam Therapy For Locally Advanced Sinonasal Malignancies  (View details on clinicaltrial.gov) Phase II
10-206 A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors requiring Partial Brain Irradiation: An Assessment of Long-term Neurocognitive, Neuroendocrine and Ototoxicity Outcomes  (View details on clinicaltrial.gov) Phase II
11-085 A Phase II Study of Reduced Intensity, Double Umbilical Cord Blood Transplantation Using Fludarabine, Melphalan, and Low Dose Total Body Radiation  (View details on clinicaltrial.gov) Phase II
15-334 A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia  (View details on clinicaltrial.gov) Phase II
14-508 A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for patients with Newly Diagnosed Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
11-208 A Phase II Trial of Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer With Involvement of Bone  (View details on clinicaltrial.gov) Phase II
11-344 A Phase II Trial of HKI-272 (Neratinib) for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases  (View details on clinicaltrial.gov) Phase II
14-370 A Phase II Trial of Integrating Stereotactic Body Radiation Therapy with Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer  (View details on clinicaltrial.gov) Phase II
05-326 A Phase II Trial of Proton Radiation For The Treatment Of Pediatric Bone And Non- Rhabdomyosarcoma Soft Tissue Sarcomas  (View details on clinicaltrial.gov) Phase II
04-188 A Phase II Trial of Proton Radiation for the Treatment of Pediatric Rhabdomyosarcoma  (View details on clinicaltrial.gov) Phase II
13-086 A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity  (View details on clinicaltrial.gov) Phase II
15-387 A phase II, multicenter, four-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease  (View details on clinicaltrial.gov) Phase II
14-527 A Phase II, Multi-Center, Single- Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carinoma of the Head and Neck (SCCHN)  (View details on clinicaltrial.gov) Phase II
14-062 A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain  (View details on clinicaltrial.gov) Phase II
14-126 A Phase II, Open-label, Study in Subjects with BRAF V600E Mutated Rare Cancers with Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib.  (View details on clinicaltrial.gov) Phase II
14-530 A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)  (View details on clinicaltrial.gov) Phase II
14-029 A Phase II, Two-Tier study evaluating the efficacy and safety of Selinexor (KPT-330)in patients with recurrent Glioblastoma after failure of Radiation Thearpy and Temozolomide  (View details on clinicaltrial.gov) Phase II
14-565 A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (MONALEESA-7)  (View details on clinicaltrial.gov) Phase III
14-221 A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)  (View details on clinicaltrial.gov) Phase III
15-111 A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations  (View details on clinicaltrial.gov) Phase III
15-232 A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advance Renal Cell Carcinoma [IMmotion151]  (View details on clinicaltrial.gov) Phase III
14-506 A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)  (View details on clinicaltrial.gov) Phase III
14-105 A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone as Second-Line Therapy in Patients with Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer  (View details on clinicaltrial.gov) Phase III
14-185 A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane) as Maintenance Treatment After Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase III
13-075 A Pilot Feasibility Study of Definitive Concurrent Chemoradiation with Pencil Beam Scanning Proton Beam in Combination with 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal  (View details on clinicaltrial.gov) N/A
14-275 A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma  (View details on clinicaltrial.gov) N/A
14-421 A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated with Chemoradiation or Immunotherapy  (View details on clinicaltrial.gov) N/A
12-213 A Prospective Study of HCV-RNA Kinetics During Treatment With SORAFENIB In Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C  (View details on clinicaltrial.gov) Phase IV
13-327 A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer  (View details on clinicaltrial.gov) Phase II
13-021 A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma  (View details on clinicaltrial.gov) Phase II
13-170 A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase 1B Dose-Escalation Portion) in Patients with Advanced or Metastatic Renal Cell Carcinoma  (View details on clinicaltrial.gov) Phase I
13-048 A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)  (View details on clinicaltrial.gov) Phase II
12-258 A Randomized Phase II Trial of Neoadjuvant Cisplatin vs Doxorubicin/Cyclophosphamide (AC) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations  (View details on clinicaltrial.gov) Phase II
13-630 A Randomized Phase IIB Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)  (View details on clinicaltrial.gov) Phase II
12-355 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma  (View details on clinicaltrial.gov) N/A
15-204 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with advanced or Metastatic Soft Tissue Sarcoma  (View details on clinicaltrial.gov) Phase III
15-412 A Randomized, Parallel-Cohort Phase 1 Study of INCB039110 in Combination With Corticosteroids for the Treatment of Acute Graft-Versus-Host Disease  (View details on clinicaltrial.gov) Phase I
14-310 A Randomized, Phase II, Multi-centered, Placebo-controlled Study of Ipatasertib (GDC-0068), An Inhibitor of AKT, In Combination With Paclitaxel As Front-line Treatment For Patients With Metastatic Triple-Negative Breast Cancer  (View details on clinicaltrial.gov) Phase II
10-106 A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)  (View details on clinicaltrial.gov) Phase III
14-375 A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
14-159 A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)  (View details on clinicaltrial.gov) Phase II
13-521 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting  (View details on clinicaltrial.gov) Phase III
13-322 A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using [11C]Temozolomide PET and Vascular MRI  (View details on clinicaltrial.gov) N/A
13-482 A Study to Evaluate Vascular Normalization in Patients with Recurrent Glioblastoma Treated with Bevacizumab using FMISO PET and Vascular MRI  (View details on clinicaltrial.gov) N/A
14-004 A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors  (View details on clinicaltrial.gov) Phase I
13-533 A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND #15380) Vaccine Given with Bevacizumab Versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)  (View details on clinicaltrial.gov) Phase II
15-701 A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)  (View details on clinicaltrial.gov) Phase III
15-700 A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)  (View details on clinicaltrial.gov) N/A
13-311 ABTC-1202:Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase I
14-233 Adcetris (Brentuximab Vedotin) Substitution Vincristine in the OEPA/COPDAC Regimen [Treatment Group 3 (TG3 of Euro-Net C1] with Involved Node Radiation Therapy for High Risk Pediatric Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov) Phase II
11-464 Afatinib Sequenced with Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial.  (View details on clinicaltrial.gov) Phase II
12-514 An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)  (View details on clinicaltrial.gov) Phase III
13-505 An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS Mutation-Positive Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
13-074 An Open-label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the anti-EGFR Antibody Panitumumab in Combination in Subjects with BRAF-mutation V600E Positive Colorectal Cancer and in Subjects with CRC With Secondary Resistance to Prior Anti-EGFR Therapy  (View details on clinicaltrial.gov) Phase II
15-212 An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy  (View details on clinicaltrial.gov) Phase I
15-546 An Open-label, Multicenter Rollover Study to Allow Continued access to Filanesib (ARRY-520) for Patients with Multiple Myeloma Who Are Currently Receiving Filanesib in Studies Sponsored by Array BioPharma Inc.  (View details on clinicaltrial.gov) N/A
15-305 An Open-Label, Multicenter, Expanded Access Program for MPDL3280A in Patients with PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer after Failure with Platinum-Containing Chemotherapy  (View details on clinicaltrial.gov) N/A
09-103 An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Tumor of Bone  (View details on clinicaltrial.gov) Phase II
14-489 An Open-Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients with ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy  (View details on clinicaltrial.gov) N/A
13-615 An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification  (View details on clinicaltrial.gov) Phase II
14-569 An Open-Label, Phase I Study of SRN-927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
11-010 An Open-Label, Phase I/II, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
13-043 An Open-Label, Phase I/IIA Study of GDC-0810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer  (View details on clinicaltrial.gov) Phase I
11-274 An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors After Progression on Prior VEGF Therapy  (View details on clinicaltrial.gov) Phase II
12-097 An Open-label, Phase II Study of Vemurafenib in Patients With BRAF V600 Mutation-positive Cancers  (View details on clinicaltrial.gov) Phase II
14-453 An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
13-272 Analysis of the kinetics and effects of vemurafenib on intratumoral and host immunity in patients with advanced BRAFV600 mutant melanoma: implications for combination with immunotherapy  (View details on clinicaltrial.gov) N/A
12-518 ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer  (View details on clinicaltrial.gov) Phase II
12-188 BMT CTN 1101: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (haplo-BM) for Patients with Hematologic Malignancies  (View details on clinicaltrial.gov) Phase III
13-453 BMT CTN 1102: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome  (View details on clinicaltrial.gov) Phase III
12-134 CALGB 30610: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide  (View details on clinicaltrial.gov) Phase III
10-327 CALGB 50801: Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)  (View details on clinicaltrial.gov) Phase II
12-440 CALGB 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma  (View details on clinicaltrial.gov) Phase II
14-096 Carfilzomib plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase I Study  (View details on clinicaltrial.gov) Phase I
08-207 Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy  (View details on clinicaltrial.gov) N/A
13-492 Clinical and Biological Predicators of Chemotherapy Toxicity in Older Adults  (View details on clinicaltrial.gov) N/A
15-032 COG AALL1232: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)  (View details on clinicaltrial.gov) Phase III
07-125 COG ACNS0332: A Phase III Study Investigating the Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients  (View details on clinicaltrial.gov) Phase III
12-389 COG ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)  (View details on clinicaltrial.gov) Phase II
09-379 COG AHEP0731: Treatment of Children with All Stages of Hepatoblastoma  (View details on clinicaltrial.gov) Phase III
13-248 COG ANBL12P1: Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma  (View details on clinicaltrial.gov) N/A
14-110 COG ANHL12P1: A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) IND # 117117  (View details on clinicaltrial.gov) Phase II
10-239 COG-ACNS0831: Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years  (View details on clinicaltrial.gov) Phase III
14-037 Dose reduction of preoperative radiotherapy in myxoid liposarcoma  (View details on clinicaltrial.gov) Phase II
15-709 E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults  (View details on clinicaltrial.gov) Phase III
09-194 E2607 - A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas  (View details on clinicaltrial.gov) Phase II
15-702 E4512: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein  (View details on clinicaltrial.gov) Phase III
11-275 ECOG 1609: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma  (View details on clinicaltrial.gov) Phase III
13-465 ECOG 3612: A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma  (View details on clinicaltrial.gov) Phase II
12-307 Evaluation of PET/MRI in Children with Cancer  (View details on clinicaltrial.gov) N/A
14-507 Expanded Access Program with Nivolumab (BMS-936558) in Combination with Ipilimumab (Yervoy) in Anti-CTLA-4 Treatment-Naïve Subjects with Unresectable or Metastatic Melanoma  (View details on clinicaltrial.gov) N/A
10-218 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma  (View details on clinicaltrial.gov) N/A
09-273 HOD08: Reduced Duration Stanford V Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
13-209 Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men with Castration-Resistant Prostate Cancer.  (View details on clinicaltrial.gov) N/A
13-428 LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis  (View details on clinicaltrial.gov) Phase III
14-056 Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer  (View details on clinicaltrial.gov) Phase II
12-023 NCCTG-N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision  (View details on clinicaltrial.gov) Phase III
13-195 Non-steroidal Anti-inflammatory Drugs (Meloxicam) to Mobilize Hematopoietic Stem Cells: A Phase II Randomized Trial  (View details on clinicaltrial.gov) Phase II
15-708 NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma  (View details on clinicaltrial.gov) Phase II
15-711 NRG-GU001: Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer  (View details on clinicaltrial.gov) Phase II
15-157 Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies  (View details on clinicaltrial.gov) Phase II
14-482 Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia(ITP)  (View details on clinicaltrial.gov) Phase II
15-306 Open-Label, Multicenter, Dose Escalation Phase IB Study with Expansion Phase to Evaluate the Safety, Pharmacokinetics and Activiity of RO5509554 and MPDL3280A Administered in Combination in Patients with Advanced Solid Tumors  (View details on clinicaltrial.gov) Phase I
15-327 Open-Label, Multi-center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma  (View details on clinicaltrial.gov) Phase III
12-466 Open-label, Phase 2 Study of Bevacizumab in Children with Neurofibromatosis 2 and Progressive Vestibular Schwannomas that are Poor Candidates for Standard Treatment with Surgery or Radiation  (View details on clinicaltrial.gov) Phase II
15-318 Oral ONC201 in Adult Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase II
11-318 Phase 1, Multicenter, Open-label, Dose-escalation Study of ACE-011 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase I
13-408 Phase 1/2 Study of PF-06463922 (an ALK/ROS1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations  (View details on clinicaltrial.gov) Phase II
15-018 Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)- Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Hepatocellular Carcinoma (HCC)  (View details on clinicaltrial.gov) Phase II
13-362 Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
14-412 Phase 2 study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients with Glioblastoma (GBM)  (View details on clinicaltrial.gov) Phase II
14-213 Phase I Dose Escalation Study of Velcade in Combination with Lenalidomide in Patients with Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation  (View details on clinicaltrial.gov) Phase I
11-072 Phase I Dose Escalation Study to Determine the MTD and DLTs of Preoperative or Definitive Administration of Nilotinib Given Concurrently with Radiation for Patients with High Risk Chordoma  (View details on clinicaltrial.gov) Phase I
15-142 Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis  (View details on clinicaltrial.gov) Phase I
13-198 Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer  (View details on clinicaltrial.gov) Phase I
13-010 Phase I Dose-Escalation, Safety, Pharmacokinetics and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies  (View details on clinicaltrial.gov) Phase I
12-267 Phase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)  (View details on clinicaltrial.gov) Phase I
14-186 Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in BRAF-Inhibitor Resistant Patients With BRAF-Mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase I
14-200 Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults  (View details on clinicaltrial.gov) Phase I
13-115 Phase I Study of Olaparib and Temozolomide in Adult Patients with Recurrent/Metastatic Ewing's Sarcoma following failure of prior chemotherapy  (View details on clinicaltrial.gov) Phase I
14-523 Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases  (View details on clinicaltrial.gov) N/A
12-159 Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer  (View details on clinicaltrial.gov) Phase I
12-396 Phase I Trial of Bevacizumab, Metronomic Doxorubicin, and Radiation Therapy for Resectable Soft Tissue Sarcomas  (View details on clinicaltrial.gov) Phase I
13-239 Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)  (View details on clinicaltrial.gov) Phase I
12-094 Phase I Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-vs.-Host Disease(GVHD)  (View details on clinicaltrial.gov) Phase I
13-040 Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)  (View details on clinicaltrial.gov) Phase I
13-363 Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)  (View details on clinicaltrial.gov) Phase I
09-293 Phase I/II Study of Cediranib and Olaparib in Combination for Treatment of Recurrent Papillary-Serous Ovarian, Fallopian Tube, or Peritoneal Cancer or for Treatment of Recurrent Triple-Negative Breast Cancer  (View details on clinicaltrial.gov) Phase II
13-424 Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors  (View details on clinicaltrial.gov) Phase II
15-121 Phase I/II Study of Olaparib and Temozolomide in Patients with Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy  (View details on clinicaltrial.gov) Phase II
12-100 Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) with Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas  (View details on clinicaltrial.gov) Phase II
13-598 Phase I: LDE225 for Steroid-Refractory GVHD  (View details on clinicaltrial.gov) Phase I
14-056-RISK Phase II Double-Blind Randomized Controlled Trial of Naltrexone for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer  (View details on clinicaltrial.gov) Phase II
13-051 Phase II Feasibility Study of FOLFIRINOX-Losartan followed by Accelerated Short Course Radiation Therapy with Proton Beam for Locally Advanced Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
15-407 Phase II Randomized Trial of Continuation of Post-Transplant Maintenance with Single-Agent Lenalidomide vs. Consolidation/Maintenance with Ixazomib-Lenalidomide-Dexamethasone in Patients with Residual Myeloma  (View details on clinicaltrial.gov) Phase II
12-484 Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR  (View details on clinicaltrial.gov) Phase II
15-196 Phase II Study of Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma  (View details on clinicaltrial.gov) Phase II
10-116 Phase II Study of Dose-Adjusted EPOCH-Rituxan in Adults with Untreated Burkitt Lymphoma and c-MYC Positive Diffuse Large B-Cell Lymphoma  (View details on clinicaltrial.gov) Phase II
15-359 Phase II Study of Ibrutinib in Patients with Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing.  (View details on clinicaltrial.gov) Phase II
11-073 Phase II Study of Neoadjuvant Accelerated Short Course Radiation Therapy with Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
11-328 Phase II Study of Preoperative FOLFIRINOX followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
14-218 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable and Borderline Resectable Pancreatic Cancer  (View details on clinicaltrial.gov) Phase II
09-263 Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors; Evaluation of Acute and Late Side Effects  (View details on clinicaltrial.gov) Phase II
10-439 Phase II Study of Proton Radiation Therapy for Low Grade Gliomas  (View details on clinicaltrial.gov) Phase II
13-443 Phase II Study of Proton Radiation Therapy for Neuroblastoma  (View details on clinicaltrial.gov) Phase II
12-456 Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors  (View details on clinicaltrial.gov) Phase II
12-091 Phase II Trial of Cabozantinib (XL184) in Patients with Advanced Solid (Non-breast, Non-prostate) Malignancies and Bony Metastases  (View details on clinicaltrial.gov) Phase II
13-249 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults  (View details on clinicaltrial.gov) Phase II
14-338 Phase II Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma  (View details on clinicaltrial.gov) Phase II
15-007 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma  (View details on clinicaltrial.gov) Phase II
14-140 Phase II Trial of Natalizumab (Tysabri) plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract  (View details on clinicaltrial.gov) Phase II
15-163 Phase II Trial of Ponatinib in Patients with Bevacizumab-Refractory Glioblastoma  (View details on clinicaltrial.gov) Phase II
15-715 Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations  (View details on clinicaltrial.gov) Phase II
12-218 Phase II Trial of Sorafenib in Combination with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase II
11-497 Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Low-intermediate Risk Prostate Cancer  (View details on clinicaltrial.gov) Phase III
10-269 Pilot Study of Adjuvant Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix with Metastases to Regional Lymph Nodes  (View details on clinicaltrial.gov) N/A
14-333 Pilot Study of EGFR Inhibition with Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma  (View details on clinicaltrial.gov) N/A
13-018 Pilot study of MET-PET (L-[methyl-11C]methionine positron emission tomography) to evaluate for treatment response after chemoradiation therapy for newly-diagnosed glioblastoma  (View details on clinicaltrial.gov) N/A
10-205 Pilot Study of Proton Radiation Therapy for Invasive Carcinoma of the Left Breast Following Mastectomy  (View details on clinicaltrial.gov) N/A
14-344 Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices  (View details on clinicaltrial.gov) Phase IV
09-361 Proton beam Radiotherapy for Medulloblastoma and Pineoblastoma: An Assessment of Acute Toxicity and Long-term Neurocognitive, Neuroendocrine and Ototoxicity Outcomes  (View details on clinicaltrial.gov) Phase II
12-504 Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation  (View details on clinicaltrial.gov) Phase II
15-185 Randomized Phase II Study Comparing Selumetinib to Placebo for Enhancing the Clinical Efficacy of Radioactive Iodine (RAI) for RAI-Avid Recurrent/Metastatic Thyroid Cancers Uptake  (View details on clinicaltrial.gov) Phase II
11-436 Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer  (View details on clinicaltrial.gov) Phase II
15-287 Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib  (View details on clinicaltrial.gov) Phase III
09-042 RRP450 - Phase I Trial in Liver Metastases and Primary Liver Tumors  (View details on clinicaltrial.gov) Phase I
10-095 RTOG 0815: A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer  (View details on clinicaltrial.gov) Phase III
10-040 RTOG 0926: A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Cisplatin Chemotherapy Following a Thorough Transurethral Surgical Restaging  (View details on clinicaltrial.gov) Phase II
13-295 RTOG 1112: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma  (View details on clinicaltrial.gov) Phase III
13-338 RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma  (View details on clinicaltrial.gov) Phase II
14-268 RTOG 1308: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC  (View details on clinicaltrial.gov) Phase III
14-265 Safety and Feasibility of Lenalidomide in Combination with HLA-mismatched Stem-Cell Microtranplantation as Post-Remission Therapy in Patients with High-Risk Acute Myeloid Leukemia (AML).  (View details on clinicaltrial.gov) Phase I
15-273 SARC018: A Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse Following Prior Treatment with Gemcitabine-Containing Therapy  (View details on clinicaltrial.gov) Phase II
15-332 SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment  (View details on clinicaltrial.gov) Phase III
14-409 The Impact of HER2 Heterogeneity on the Treatment of Early-Stage HER2-Positive Breast Cancer: A Phase II Study of T-DM1 in Combination with Pertuzumab in the Preoperative Setting  (View details on clinicaltrial.gov) Phase II
15-264 The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum  (View details on clinicaltrial.gov) Phase III
15-378 The ROCKET Study: A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia  (View details on clinicaltrial.gov) Phase II
299 clinical trials listed

Back to Top